P3. Immuno-modulatory agents

The available evidence suggests that the putative immuno-modulatory agent OM-85 BV is well tolerated (Sprenkle et al., 2004) [evidence level I]. However, consistent results across important clinical outcomes, such as exacerbation and hospitalisation rates, are lacking to determine whether it is effective. Further randomised, controlled trials enrolling large numbers of persons with well-defined COPD are necessary to confirm the effectiveness of this agent.